What are the side effects of Mounjaro, and when should they be medically assessed in Europe?

Mounjaro side effects explained: tirzepatide, GLP-1/GIP receptor agonist effects, gastrointestinal symptoms, metabolic changes, and prescribing criteria.

In this episode, we outline the known side effect profile of Mounjaro (tirzepatide) and how doctors monitor safety under EU medical guidance.

You’ll learn:

• Common side effects: nausea, vomiting, diarrhoea, constipation, reduced appetite

• Why dose escalation can increase gastrointestinal symptoms

• The risk of dehydration and electrolyte imbalance

• When gallbladder issues or pancreatitis must be excluded

• Potential impact on blood glucose levels

• Thyroid-related safety considerations in specific risk groups

• Red flag symptoms such as severe abdominal pain, persistent vomiting, or signs of allergic reaction

• Situations where continuation or dose increases may be declined pending review

We explain how doctors assess BMI, HbA1c, weight loss rate, gastrointestinal tolerance, medication interactions, and past medical history during an online consultation in the EU. Careful monitoring is required to balance metabolic benefits with safety considerations.

This episode reflects the clinical standards used by Mobi Doctor, where weight management consultations are reviewed by a registered physician in line with EU prescribing guidance.

Read the full guide and transcript here:

https://www.mobidoctor.eu/blog/mounjaro-side-effects-what-you-should-know